Switzerland · Delayed Price · Currency is CHF medmix AG Earnings Call Transcripts
Fiscal Year 2025
-
Gross profit and margins improved year-over-year despite revenue declines, driven by cost savings and strong dental performance. Guidance for 2026 is cautious, with flat to low single-digit organic growth and margin stability, as dual sourcing and tariffs remain headwinds.
-
Gross profit and profitability improved above guidance despite lower revenues, driven by cost savings and efficiency gains. Dental and Surgery segments outperformed, while Beauty and Industry faced headwinds. Full-year revenue is expected to decline, but margin guidance is maintained.
Fiscal Year 2024
-
Gross profit and cash flow improved in 2024 despite lower revenues, with strong dental and surgery growth offset by declines in drug delivery and industry. A CHF 30 million cost-saving program is underway, with flat revenues and EBITDA margin of 18%-19% expected for 2025.
-
Revenue declined year-over-year but improved sequentially, with gross margin gains and strong cash flow recovery driven by dental and industry segments and the Qiaoyi acquisition. Full-year guidance was revised down due to soft end market demand, but management remains optimistic about long-term growth, especially in healthcare.